Wockhardt Q1 net loss shrinks to Rs 45 crore from previous fiscal loss of Rs 89.18 crore
Total income of the company stood at Rs 871.19 crore during the quarter under review, down 14.18 per cent, from Rs 1,015.14 crore reported in the corresponding period of the previous fiscal, Wockhardt said in a BSE filing.
New Delhi: Pharmaceutical firm Wockhardt NSE -2.29 % on Wednesday reported narrowing of its consolidated net loss to Rs 44.98 crore for the quarter ended June 30, 2019.
The company had posted a net loss of Rs 89.18 crore in the same period a year ago.
Total income of the company stood at Rs 871.19 crore during the quarter under review, down 14.18 per cent, from Rs 1,015.14 crore reported in the corresponding period of the previous fiscal, Wockhardt said in a BSE filing.
The company said, during the quarter, it repaid Rs 351 crore towards various long-term debt obligations.
Total long-term outstanding debts on June 30, 2019, stood at Rs 2,119 crore compared to Rs 2,723 crore as on June 30, 2018, the company added.
Read Also: Wockhardt gets zero observations from USFDA for bioequivalence centre at Aurangabad
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd